Topics

Articles

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.

Major PBM to Offer Cost-Based Pricing Option for Prescription Medications 

Blue Fin Group exec speaks on his upcoming feature. 

Access Insights 2023: Bill Roth Talks 2024 Being the Year of "Who Moved my Prescription"

Videos

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener. 

Access Insights 2023: Bill Roth Provides an Overview of his Keynote Speech, Fight for the Dollar

Director of Berkeley Research Group explains changes to 340B moving forward. 

Access Insights 2023: Andrew Brownlee Discusses How the 340B Landscape Will Continue to Evolve Moving Forward

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing. 

Access Insights 2023: Andrew Brownlee Discusses How Manufacturers Calculate 340B Prices

Berkeley Research Group Director discusses what to expect at his upcoming session. 

Access Insights 2023: Andrew Brownlee Discusses Things to Expect in his "340B Lessons from the Field" Presentation

Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.

Lilly's Tirzepatide Gets FDA Approval for Chronic Weight Management 

Study describes how biotech startups can avoid competing with large pharma companies for financing. 

Report Explores Ways to Finance, Repurpose Rare Disease Drugs

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel. 

Prescription Sales via Traditional Healthcare Distributors Increase

Payers won’t let these products break the bank.

Market Access and Pricing